Drugs / MIL116
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07375758 | Feb 2026 → Jun 2028 expected | IgA glomerulonephritis | Beijing Mabworks Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIL116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07375758 ↗ |
| Action | Inhibit | “an anti-APRIL monoclonal antibody” NCT07375758 ↗ |
| Modality | Monoclonal antibody | “an anti-APRIL monoclonal antibody” NCT07375758 ↗ |
| Route | Subcutaneous | “subcutaneous (SC) injection” NCT07375758 ↗ |